Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice
| Autor: | Winnie Lee, Gerhard Koenig, Mary Jo Miller, Zhiyong Yang, Hilliary Hodgdon, Daniel Havas, Emily A. Freeman, Veerle Vulsteke, Holger Patzke, Liza Leventhal, Richard Chesworth, Sarah C. Hopp, Faris Albayya, Jean Francois Blain, Zhiming Tu, Michael K. Ahlijanian, Lori Hrdlicka, Louise Scrocchi, Scott Nolan, Melody Wen, Henrik Zetterberg, Dorothy G. Flood, Don Costa, Kevin M. Felsenstein, Erik Portelius, Kathryn Rogers, Gideon Shapiro, Birgit Hutter-Paier, Bart De Strooper, Darcie Spaulding |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Amyloid
Clinical Neurology Mice Transgenic Pharmacology γ-secretase lcsh:Geriatrics Transfection lcsh:RC346-429 Cellular and Molecular Neuroscience Mice Cognition In vivo Alzheimer Disease Cell Line Tumor medicine Amyloid precursor protein Animals Humans Senile plaques Receptor Molecular Biology Gamma secretase lcsh:Neurology. Diseases of the nervous system Modulation Amyloid beta-Peptides biology Behavior Animal Phenylpropionates Chemistry Biphenyl Compounds medicine.disease NSAID lcsh:RC952-954.6 biology.protein Neurology (clinical) Alzheimer's disease Amyloid Precursor Protein Secretases Propionates Amyloid precursor protein secretase Alzheimer’s disease Research Article |
| Zdroj: | Molecular Neurodegeneration, Vol 7, Iss 1, p 61 (2012) Molecular Neurodegeneration |
| ISSN: | 1750-1326 |
| Popis: | Background A hallmark of Alzheimer’s disease is the presence of senile plaques in human brain primarily containing the amyloid peptides Aβ42 and Aβ40. Many drug discovery efforts have focused on decreasing the production of Aβ42 through γ-secretase inhibition. However, identification of γ-secretase inhibitors has also uncovered mechanism-based side effects. One approach to circumvent these side effects has been modulation of γ-secretase to shift Aβ production to favor shorter, less amyloidogenic peptides than Aβ42, without affecting the overall cleavage efficiency of the enzyme. This approach, frequently called γ-secretase modulation, appears more promising and has lead to the development of new therapeutic candidates for disease modification in Alzheimer’s disease. Results Here we describe EVP-0015962, a novel small molecule γ-secretase modulator. EVP-0015962 decreased Aβ42 in H4 cells (IC50 = 67 nM) and increased the shorter Aβ38 by 1.7 fold at the IC50 for lowering of Aβ42. AβTotal, as well as other carboxyl-terminal fragments of amyloid precursor protein, were not changed. EVP-0015962 did not cause the accumulation of other γ-secretase substrates, such as the Notch and ephrin A4 receptors, whereas a γ-secretase inhibitor reduced processing of both. A single oral dose of EVP-0015962 (30 mg/kg) decreased Aβ42 and did not alter AβTotal peptide levels in a dose-dependent manner in Tg2576 mouse brain at an age when overt Aβ deposition was not present. In Tg2576 mice, chronic treatment with EVP-0015962 (20 or 60 mg/kg/day in a food formulation) reduced Aβ aggregates, amyloid plaques, inflammatory markers, and cognitive deficits. Conclusions EVP-0015962 is orally bioavailable, detected in brain, and a potent, selective γ-secretase modulator in vitro and in vivo. Chronic treatment with EVP-0015962 was well tolerated in mice and lowered the production of Aβ42, attenuated memory deficits, and reduced Aβ plaque formation and inflammation in Tg2576 transgenic animals. In summary, these data suggest that γ-secretase modulation with EVP-0015962 represents a viable therapeutic alternative for disease modification in Alzheimer’s disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|